TMO Thermo Fisher Scientific, Inc.

All TMO filings Filing statistics SEC Website

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Company profile

Ticker

TMO

Exchange

NYSE

CEO

Marc N. Casper

Incorporated in

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Health Technology > Medical Specialties

Industry (SEC)

Measuring & Controlling Devices, NEC

Rockwell Automation • Trimble • Cubic • MTS Systems • Geospace Technologies • Nanometrics • FARO • Cemtrex • Image Sensing Systems • Flexpoint Sensor Systems ...

Former names

Thermo Electron Corp

SEC CIK

0000097745

Corporate docs

Articles of Incorporation & Bylaws

IRS number

42209186

TMO stock data

S&P 500

1M 1Y 2Y 5Y

Company financial data Financial data

Chart TMO financial data

Download latest Excel data (2019 Q2) View latest Excel data (2019 Q2)

Quarter (USD)	Jun 19	Mar 19	Dec 18	Sep 18
Revenue	6.32B	6.13B	6.51B	5.92B
Net income	1.12B	815M	898M	709M
Diluted EPS	2.77	2.02	2.22	1.75
Net profit margin	17.72%	13.31%	13.80%	11.98%
Operating income	1.5B	920M	1.15B	912M
Net change in cash	1.18B	-997M	1.01B	161M
Cash on hand	2.29B	1.11B	2.1B	1.1B
Cost of revenue

Annual (USD)	Dec 18	Dec 17	Dec 16	Dec 15
Revenue	24.36B	20.92B	18.27B	16.97B
Net income	2.94B	2.23B	2.02B	1.98B
Diluted EPS	7.24	5.59	5.09	4.92
Net profit margin	12.06%	10.64%	11.06%	11.64%
Operating income	3.78B	2.96B	2.46B	2.34B
Net change in cash	768M	549M	333.9M	-891.4M
Cash on hand	2.1B	1.34B	786M	452.1M
Cost of revenue		2.5B	1.69B	1.63B

Financial data from company earnings reports

Financial report summary

Competition

Bio-Rad Laboratories • Dionex • Mesa Laboratories • Accelerate Diagnostics • Waters • Molecular Devices • Caliper Life Sciences • Luminex • Cepheid • Biocept

Management Discussion

Sales in the second quarter of 2019 were $6.32 billion, an increase of $238 million from the second quarter of 2018. Sales increased $54 million due to acquisitions. The unfavorable effects of currency translation resulted in a decrease in revenues of $132 million in 2019. Aside from the effects of acquisitions/divestitures and currency translation, revenues increased $316 million (5%) primarily due to increased demand in the quarter compared to the 2018 quarter. Sales to customers in each of the company's primary end markets grew except for sales to academic and government customers which were flat. Sales to customers in the biotech and pharmaceutical industry were particularly strong. Sales growth was strong in Asia and North America and moderate in Europe.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Cork, divested, exceeded, hand, Ireland, proposed, repaid, site, substance, weaker

Removed: abandoning, closing, combination, depreciation, determine, electron, exited, favorable, fund, instrumentation, repurchased

From filing 10-Q 2019 Q2